Dyne Therapeutics (NASDAQ:DYN) Insider Johanna Friedl-Naderer Sells 900 Shares

by · The Markets Daily

Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) insider Johanna Friedl-Naderer sold 900 shares of the company’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $24.35, for a total transaction of $21,915.00. Following the completion of the transaction, the insider owned 153,082 shares of the company’s stock, valued at $3,727,546.70. This trade represents a 0.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Johanna Friedl-Naderer also recently made the following trade(s):

  • On Tuesday, September 8th, Johanna Friedl-Naderer sold 185 shares of Dyne Therapeutics stock. The stock was sold at an average price of $18.88, for a total transaction of $3,492.80.

Dyne Therapeutics Stock Performance

Shares of DYN stock opened at $20.31 on Wednesday. Dyne Therapeutics, Inc. has a 12 month low of $11.92 and a 12 month high of $27.31. The company has a debt-to-equity ratio of 0.28, a current ratio of 12.02 and a quick ratio of 12.02. The firm has a market capitalization of $3.79 billion, a P/E ratio of -6.10 and a beta of 1.08. The company’s fifty day moving average price is $24.82 and its two-hundred day moving average price is $20.49.

Dyne Therapeutics (NASDAQ:DYN – Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.33). On average, research analysts anticipate that Dyne Therapeutics, Inc. will post -3.47 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Dyne Therapeutics

Hedge funds have recently bought and sold shares of the company. AQR Capital Management LLC bought a new stake in Dyne Therapeutics in the first quarter valued at about $246,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Dyne Therapeutics by 5.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,466 shares of the company’s stock worth $597,000 after buying an additional 2,886 shares during the last quarter. Goldman Sachs Group Inc. grew its position in shares of Dyne Therapeutics by 58.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 994,886 shares of the company’s stock worth $10,407,000 after acquiring an additional 366,183 shares in the last quarter. Caxton Associates LLP acquired a new position in shares of Dyne Therapeutics in the 1st quarter worth approximately $157,000. Finally, Creative Planning increased its holdings in shares of Dyne Therapeutics by 23.8% in the 2nd quarter. Creative Planning now owns 14,541 shares of the company’s stock valued at $138,000 after acquiring an additional 2,797 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Dyne Therapeutics

Here are the key news stories impacting Dyne Therapeutics this week:

  • Positive Sentiment: Dyne announced that it will present additional six- and 12-month data from the Phase 1/2 ACHIEVE trial of z-basivarsen (DYNE-101) at the World Muscle Society and AANEM meetings beginning September 29-30. The data will include comparisons with a matched natural-history cohort and updated safety results. Dyne ACHIEVE trial data announcement
  • Positive Sentiment: The ACHIEVE registrational expansion cohort is fully enrolled, and Dyne expects topline results in the first quarter of 2027. DYNE-101 also has FDA Breakthrough Therapy, Orphan Drug and Fast Track designations, supporting the potential for an expedited development path. Quiver Quantitative ACHIEVE summary
  • Neutral Sentiment: Call-option activity surged, with traders purchasing approximately 20,532 calls versus average daily volume of about 464. This may reflect speculative expectations for a rebound or upcoming data, but options activity does not confirm a fundamental improvement.
  • Negative Sentiment: Reports said DYN fell heavily after a rival DM1 drug failed in Phase 3. Investors appear concerned that the setback could signal clinical or commercial risks for the DM1 field, even though Dyne’s own upcoming one-year data have not yet been released. RTT News report on rival DM1 failure
  • Negative Sentiment: Several executives, including CEO John Cox, reported stock sales. The transactions were made to cover tax withholding on vested equity awards and were relatively small compared with their remaining holdings, limiting their direct significance, but the cluster of sales may add to cautious sentiment.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Sanford C. Bernstein raised their price objective on Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a research note on Wednesday, May 13th. Cantor Fitzgerald initiated coverage on Dyne Therapeutics in a research report on Thursday, July 23rd. They issued an “overweight” rating on the stock. Royal Bank Of Canada increased their target price on Dyne Therapeutics from $30.00 to $35.00 and gave the company an “outperform” rating in a research note on Thursday, July 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Friday, July 17th. Finally, HC Wainwright restated a “buy” rating and issued a $50.00 price target on shares of Dyne Therapeutics in a research note on Monday, August 17th. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Dyne Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $34.17.

Check Out Our Latest Analysis on DYN

About Dyne Therapeutics

(Get Free Report)

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.

Further Reading